Paroxysmal Cold Hemoglobinuria
Symptoms, Doctors, Treatments, Advances & More

Paroxysmal Cold Hemoglobinuria Overview

Save information for later
Sign Up

Learn About Paroxysmal Cold Hemoglobinuria

Condition 101 content is not available at this time, but we are continually updating the site. Please check back.

However, there may be experts who have treated this or similar conditions in our Find a Doctor section and research may be available in our Latest Advances section.

Who are the top Paroxysmal Cold Hemoglobinuria Local Doctors?
Robert A. Brodsky
Elite in Paroxysmal Cold Hemoglobinuria
Pathology | Hematology | Oncology
Elite in Paroxysmal Cold Hemoglobinuria
Pathology | Hematology | Oncology

Sidney Kimmel Comprehensive Cancer Center

401 North Broadway Street, Weinberg BLDG, Weinberg BLDG, 
Baltimore, MD 
Languages Spoken:
English

Dr. Robert Brodsky is a professor of medicine at the Johns Hopkins University School of Medicine. His area of clinical expertise is classical hematology and haploidentical bone marrow transplant for sickle cell disease and aplastic anemia. Dr. Brodsky serves as the director of the Division of Hematology and the T32 Training Program. He is the Johns Hopkins Family Professor of Medicine and Oncology. He received his M.D. from Hahnemann University. He completed his residency at the Vanderbilt University School of Medicine. He performed a fellowship in hematology at the National Institutes of Health and a fellowship in oncology at Johns Hopkins. He joined the Johns Hopkins faculty in 1997. From 2017 to 2022 he served as Associate Editor to The Journal of Clinical Investigation (JCI) and Secretary to American Society of Hematology (ASH). He serves as President of The American Society of Hematology (ASH) in 2023. Dr. Brodsky is rated as an Elite provider by MediFind in the treatment of Paroxysmal Cold Hemoglobinuria. His top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, Anemia, Bone Marrow Transplant, and Splenectomy.

Jaroslaw Maciejewski
Elite in Paroxysmal Cold Hemoglobinuria
Elite in Paroxysmal Cold Hemoglobinuria

Cleveland Clinic

8950 Euclid Ave, 
Cleveland, OH 
Languages Spoken:
English
Offers Telehealth

Jaroslaw Maciejewski is a Hematologist in Cleveland, Ohio. Dr. Maciejewski is rated as an Elite provider by MediFind in the treatment of Paroxysmal Cold Hemoglobinuria. His top areas of expertise are Paroxysmal Nocturnal Hemoglobinuria (PNH), Aplastic Anemia, Paroxysmal Cold Hemoglobinuria, Bone Marrow Transplant, and Splenectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Phillip Scheinberg
Elite in Paroxysmal Cold Hemoglobinuria
Hematology | Oncology
Elite in Paroxysmal Cold Hemoglobinuria
Hematology | Oncology

Office

Calais, ME 
Languages Spoken:
English

Phillip Scheinberg is a Hematologist and an Oncologist in Calais, Maine. Dr. Scheinberg is rated as an Elite provider by MediFind in the treatment of Paroxysmal Cold Hemoglobinuria. His top areas of expertise are Aplastic Anemia, Anemia, Paroxysmal Nocturnal Hemoglobinuria (PNH), Paroxysmal Cold Hemoglobinuria, and Bone Marrow Transplant.

What are the latest Paroxysmal Cold Hemoglobinuria Clinical Trials?
National Longitudinal Cohort of Hematological Diseases (NICHE)

Summary: Background Hematological diseases are disorders of the blood and hematopoietic organs. The current hematological cohorts are mostly based on single-center or multi-center cases, or cohorts with limited sample size in China. There is a lack of comprehensive and large-scale prospective cohort studies in hematology. The purpose of this study is to analyze the incidence and risk factors of major blood...

Match to trials
Find the right clinical trials for you in under a minute
Get started
Observational Study of Ultomiris® (Ravulizumab) Safety in Pregnancy

Summary: The primary objective of this study is to describe the frequency and characteristics of pregnancy outcomes and maternal complications among participants exposed to Ultomiris and to describe the frequency and characteristics of selected fetal/neonatal/infant outcomes in utero, at birth, and through 1 year of age after exposure in utero or via breastmilk.